Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citysky: CIT-013 in Healthy Adult Volunteers
NCT07499908Phase 1Completed
- Sponsor
- Citryll
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease comparing CIT-013 high dose with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 weeks. Started Jun 2026; status: completed.
02
Drugs
CIT013
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07499908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499908.